Healthy Subjects Clinical Trial
Official title:
Bioavailability and Pharmacokinetic Parameters of Mango Pulp Phytochemicals in Human Plasma
The primary objectives of the study are:
1. To investigate the relative bioavailability and absorption/kinetic profile of
phytochemicals after acute consumption of mango pulp.
2. To study the systemic accumulation or generation of new mango pulp phytochemicals /their
metabolites in blood after regular mango intake for an extended time frame.
3. To enhance the bioavailability of polyphenols in mango pulp by addition of Vitamin C to
the mango pulp.
The trial is designed as a randomized, 3 arm, within-subject crossover, study design.
Subjects meeting eligibility criteria will participate in 3 in-lab visits where they will
receive 1 of 3 treatments: Mango (pulp/flesh) (500 g), Mango (500 g) + Vitamin C (100 mg) or
Vitamin C (100 mg) only. The study day visit will last for approximately 10.5 h with a follow
up visit the next day (24 h) for blood and urine collection to allow for the characterization
of target mango pulp phytochemicals and metabolites in plasma and urine. And then after a
2-week wash out period, a 14-day feeding trial will be conducted in which subjects will be
given mango pulp (500 g) to take home and instructed to consume every day for 14 days, to
study the accumulation of polyphenols and their metabolites in blood. A fasting blood sample
will be collected on day 1 of the trial and then again on the 15th day.
Subjects will be required to meet several inclusion and exclusion criteria, which will be
assessed through online survey and on-site clinic assessments, including questionnaires,
blood analysis and anthropometric measures. Eligible subjects will be invited to participate
in the study.
During the Screening Visit, subjects will read, sign and date a written Institutional Review
Board approved Informed Consent Form prior to performing any study procedure. And then they
will be assessed their qualification, if eligible to participate, subjects will be instructed
on the process for completing study questionnaires and counseled to restrict intake of
colored plant foods rich in phytonutrients the 7 days prior to each Study Day. They will be
asked to restrict alcohol intake, coffee/tea/ caffeinated beverage intake and moderate /
vigorous physical activity and to drink plenty of water to maintain hydration in the 24 h
prior to each Study Day. They will be instructed to come to the Clinical Nutrition Research
Center (CNRC) the day before each Study Day to pick up their dinner meal and evening snack.
Subjects will be asked to get a usual night of sleep and to come to the CNRC after a 10-h
overnight fasting on each Study Day.
Each study visit will involve with blood samples collection at time points 0 (fasting), 0.5,
1, 2, 3, 4, 6, 7, 8, 9 10 and 24 hour (h) for assessment of change in plasma and metabolites.
A drink will be provided immediately after the 0 h blood collection, a breakfast meal will be
provided immediately after the 2 h blood collection, and lunch after 6 h blood collection.
Urine samples will be collected at 0 (fasting)-2, 2-6, 6-10 and 24 h.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05483998 -
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT02235012 -
Cognitive Biases Under Ketamine
|
N/A | |
Recruiting |
NCT02417714 -
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
|
||
Completed |
NCT04418973 -
Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject.
|
N/A | |
Completed |
NCT05088343 -
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06248801 -
Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets
|
Phase 1 | |
Terminated |
NCT04068259 -
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03279302 -
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06233162 -
Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
|
Phase 1 | |
Recruiting |
NCT04159844 -
Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects
|
N/A | |
Completed |
NCT06137911 -
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
|
Phase 1 | |
Completed |
NCT04849286 -
Measurement of HTL0016878 in Cerebrospinal Fluid
|
Phase 1 | |
Not yet recruiting |
NCT06233227 -
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
|
Phase 1 | |
Completed |
NCT04096157 -
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
|
Phase 1 | |
Completed |
NCT01200368 -
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
|
Phase 3 | |
Recruiting |
NCT05805033 -
Peri-Implant Soft Tissue Integration in Humans: Influence of Material
|
N/A | |
Completed |
NCT04027803 -
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
|
Phase 1 | |
Recruiting |
NCT03467880 -
Multicenter Study of Impulse Oscillometry in Chinese
|
N/A | |
Completed |
NCT02903095 -
Single Ascending Dose Study of TD-1439 in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02341508 -
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
|
Phase 1 |